[
  {
    "ts": "2026-01-15T18:52:01+00:00",
    "headline": "Amgen Inc. (AMGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Amgen Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $325.54 as of January 12th. AMGN’s trailing and forward P/E were 25.18 and 14.79 respectively according to Yahoo Finance. Amgen Inc. discovers, develops, manufactures, and […]",
    "url": "https://finance.yahoo.com/news/amgen-inc-amgn-bull-case-185201672.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ff1df915-6506-387d-aac5-abcb25cdeec2",
      "content": {
        "id": "ff1df915-6506-387d-aac5-abcb25cdeec2",
        "contentType": "STORY",
        "title": "Amgen Inc. (AMGN): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Amgen Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $325.54 as of January 12th. AMGN’s trailing and forward P/E were 25.18 and 14.79 respectively according to Yahoo Finance. Amgen Inc. discovers, develops, manufactures, and […]",
        "pubDate": "2026-01-15T18:52:01Z",
        "displayTime": "2026-01-15T18:52:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a49b9a42a2102b33fd69d5d1f482ffdd",
          "originalWidth": 1383,
          "originalHeight": 1357,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Xzp1nABkg1Z_KZox7tLV6g--~B/aD0xMzU3O3c9MTM4MzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/a49b9a42a2102b33fd69d5d1f482ffdd.cf.webp",
              "width": 1383,
              "height": 1357,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZVLFBt7KfNPokWhilQ0rCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a49b9a42a2102b33fd69d5d1f482ffdd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-inc-amgn-bull-case-185201672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-inc-amgn-bull-case-185201672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T21:40:00+00:00",
    "headline": "Amgen’s Weight-Loss Drug Shows Promise With Less Frequent Dosing",
    "summary": "Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.",
    "url": "https://www.barrons.com/articles/amgen-maritide-obesity-drug-phase-2-weight-loss-6325caa1?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "5c5403ac-7621-3c42-9863-01d7e8cf9774",
      "content": {
        "id": "5c5403ac-7621-3c42-9863-01d7e8cf9774",
        "contentType": "STORY",
        "title": "Amgen’s Weight-Loss Drug Shows Promise With Less Frequent Dosing",
        "description": "",
        "summary": "Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.",
        "pubDate": "2026-01-15T21:40:00Z",
        "displayTime": "2026-01-15T21:40:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/5c5403ac-7621-3c42-9863-01d7e8cf9774/amgen%E2%80%99s-weight-loss-drug.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/359156d7861a34f6a3b83a291570ae77",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PNrMsDOs5RJdIGqpAGv9sQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/359156d7861a34f6a3b83a291570ae77.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qlmwGp_Gbo8NdueGARqDFQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/359156d7861a34f6a3b83a291570ae77.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/amgen-maritide-obesity-drug-phase-2-weight-loss-6325caa1?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]